This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Timothy J. Wilt, MD, MPH; Anne M. Joseph, MD, MPH; Kristine E. Enstud, MD, MPH
University of Minnesota Minneapolis

JAMA. 1992;268(22):3198-3199.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We read with interest the article by Johansson et al¹ and the Editorial by Oesterling² regarding screening and treatment for prostate cancer. We agree with Johansson et al "that without evidence of benefit from controlled clinical trials, the radical treatment of early-stage prostate cancer remains in its experimental phase." We disagree with the editorial statement by Oesterling that recommends "a serum... PSA concentration and... DRE. If both are normal, the patient should be followed with annual evaluations..." [his italics]. This statement is not convincingly supported by the medical literature or the majority of expert panel recommendations.^3,4 Such an editorial position is of particular concern because an ongoing national prostate cancer screening program, organized and sponsored by a pharmaceutical corporation, also pressures physicians to adopt screening strategies of unproven benefit.

The Schering Corporation, manufacturer of flutamide, has sponsored National Prostate Cancer Awareness Week (PCAW) for . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?